LaunchPad Medical, Inc. is primarily involved with the development of an injectable, self-setting osteoconductive bone adhesive material (Tetranite®). While the company’s focus is to use this technology within the dental market, they have also been working on developing adhesive applications for a larger scope of the orthopedics market.
M2D2, its resident companies, and the medical device and biotech innovation community in Lowell and Worcester are pleased to welcome RQMIS Inc. as an M2D2 Platinum Corporate Sponsor.
Based in Amesbury, Massachusetts and with sister companies in the UK and Spain, RQMIS provides therapeutically focused, comprehensive regulatory consultation to the global medical device, pharmaceutical, combination product, dietary supplement and human tissue industry. As part of its M2D2 Sponsorship, RQMIS will participate in the $200K Challenge, including the call for applications, applicant screening, and judging the final competition showcase. Regularly throughout the year, RQMIS will offer educational sessions and host office hours to provide mentoring and share insights with M2D2 resident start-up companies.
This year has brought many exciting achievements for M2D2 resident companies—and here’s one more. Glyscend, a polymer therapeutics company focused on revolutionizing Type 2 diabetes treatment, has been named one of two startup labs selected to receive funding from Breakout Labs. Glyscend operates facilities at both M2D2 in Lowell and at the Johns Hopkins Fast Forward facility in Baltimore.
This spring UMass Lowell Department of Chemical Engineering, and the UML’s Massachusetts Biomanufacturing Center received funding through the Massachusetts Life Science Center “Building Breakthroughs” program. The funding will support continuous bioprocessing manufacturing as an alternative to batch manufacturing. This new process is being explored in the manufacturing of small molecule drugs by the pharmaceutical industry. The research grant is part of a consortium that includes the M2D2 resident company (and 2018 $200K Challenge finalist) Versatope Therapeutics, who have developed an exosome-like vesicle technology currently used for vaccines. With this funding, these organizations are creating a truly transformative “continuous manufacturing” process for biopharmaceutical manufacturing. Continue reading →
We’re thrilled to spread the word that one of our innovative resident companies, LivOnyx, has been named one of five 2019 winners in the Massachusetts Life Sciences Center (MSLC) Massachusetts Next Generation Initiative. LivOnyx will receive $87,500 in funding, as well as access for a year to a network of executive coaches.
The BARDA DRIVe team is pleased to announce that the new, easy-to-use EZ BAA online Portal is now live as of April 23, 2019. This Portal will replace the existing PDF-based process, helping to improve the user experience, data integrity, and data security. The system will also streamline internal processes, helping DRIVe’s program teams continue to make awards in as few as 30 days.
Some 200 life sciences innovators, investors, and insiders crowded the offices of Mintz in downtown Boston last night as we announced the winners of the 8th annual M2D2 $200K Challenge. Out of a field of 19 Finalists, our judges selected 12 winners—a Challenge record.
With support from the Deshpande Foundation, three finalist startups from an incubator in Chennai, India were able to pitch their life sciences innovations in Lowell on March 27. Not only did they compete, but they were also able to immerse themselves first-hand in the burgeoning biotech ecosystem that’s making Boston and environs the talk of the innovation economy.
Dynocardia is 1 of 19 finalists chosen to pitch at the $200K Challenge Pitch-Off last Wednesday. Dynocardia’s ViTrack™ is the first-of-its-kind, standalone, cuff-less, wearable device for continuous non-invasive blood pressure monitoring.
Mohan Thanikachalam, CEO of Dynocardia, offers us an exclusive inside look behind the development of the ViTrackTM!